Novelos Therapeutics is a pharmaceutical company engaged in the development of novel drugs to treat and diagnose cancer. The company’s cancer-targeted compounds are selectively taken up and retained in cancer cells – including cancer stem cells versus normal cells. Novelos’ therapeutic compounds, therefore, appear to directly kill cancer cells while reducing the harm to normal cells, potentially providing efficacy versus the three primary drivers of mortality in cancer: primary tumors, metastases  and stem cell-based relapse. For more information, visit the company’s Web site at www.novelos.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: